Contrasting Eloxx Pharmaceuticals (ELOX) & Its Competitors

Eloxx Pharmaceuticals (NASDAQ: ELOX) is one of 40 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its risk, institutional ownership, valuation, analyst recommendations, earnings, profitability and dividends.


This table compares Eloxx Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Eloxx Pharmaceuticals N/A -144.83% -86.63%
Eloxx Pharmaceuticals Competitors -58.02% -6.41% -3.76%

Earnings and Valuation

This table compares Eloxx Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Eloxx Pharmaceuticals N/A -$50.87 million -2.08
Eloxx Pharmaceuticals Competitors $1.40 billion $67.03 million 9.17

Eloxx Pharmaceuticals’ peers have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Eloxx Pharmaceuticals has a beta of 2.6, suggesting that its share price is 160% more volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ peers have a beta of 5.75, suggesting that their average share price is 475% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Eloxx Pharmaceuticals and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals 0 0 1 0 3.00
Eloxx Pharmaceuticals Competitors 217 977 1838 86 2.58

As a group, “Commercial physical research” companies have a potential upside of 5.21%. Given Eloxx Pharmaceuticals’ peers higher possible upside, analysts plainly believe Eloxx Pharmaceuticals has less favorable growth aspects than its peers.

Institutional and Insider Ownership

21.7% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.9% of shares of all “Commercial physical research” companies are owned by institutional investors. 33.4% of Eloxx Pharmaceuticals shares are owned by insiders. Comparatively, 17.1% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.


Eloxx Pharmaceuticals peers beat Eloxx Pharmaceuticals on 9 of the 13 factors compared.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with's FREE daily email newsletter.